
First Wave BioPharma, Inc. – NASDAQ:FWBI
First Wave BioPharma stock price today
First Wave BioPharma stock price monthly change
First Wave BioPharma stock price quarterly change
First Wave BioPharma stock price yearly change
First Wave BioPharma key metrics
Market Cap | 5.99M |
Enterprise value | 1.17M |
P/E | -0.1 |
EV/Sales | N/A |
EV/EBITDA | -0.08 |
Price/Sales | N/A |
Price/Book | 0.60 |
PEG ratio | N/A |
EPS | -45.48 |
Revenue | N/A |
EBITDA | -20.90M |
Income | -6.15M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeFirst Wave BioPharma stock price history
First Wave BioPharma stock forecast
First Wave BioPharma financial statements
Jun 2023 | 0 | -4.18M | |
---|---|---|---|
Sep 2023 | 0 | -3.43M | |
Dec 2023 | 138.76K | -4.10M | -2955.25% |
Mar 2024 | 0 | 5.56M |
2025 | 16.47M | -32.12M | -195% |
---|---|---|---|
2026 | 22.26M | -42.26M | -189.84% |
2027 | 27.50M | -733.22K | -2.67% |
2028 | 58.14M | 154.71K | 0.27% |
Analysts Price target
Financials & Ratios estimates
2022-11-14 | -21.07 | 18.2 |
---|---|---|
2023-03-20 | -30.87125 | -9.47 |
Jun 2023 | 4327871 | 3.44M | 79.62% |
---|---|---|---|
Sep 2023 | 5927269 | 2.64M | 44.68% |
Dec 2023 | 6883195 | 3.28M | 47.66% |
Mar 2024 | 91133902 | 13.26M | 14.56% |
Jun 2023 | -2.76M | 0 | 1.93M |
---|---|---|---|
Sep 2023 | -3.33M | 0 | 5.38M |
Dec 2023 | -3.43M | -500K | 4.35M |
Mar 2024 | -3.74M | 88.16K | 3.37M |
First Wave BioPharma alternative data
Aug 2023 | 10 |
---|---|
Sep 2023 | 10 |
Oct 2023 | 10 |
Nov 2023 | 10 |
Dec 2023 | 10 |
Jan 2024 | 10 |
Feb 2024 | 10 |
Mar 2024 | 10 |
Apr 2024 | 10 |
May 2024 | 9 |
Jun 2024 | 9 |
Jul 2024 | 9 |
First Wave BioPharma other data
Period | Buy | Sel |
---|---|---|
Jul 2023 | 0 | 5326 |
Aug 2023 | 0 | 6053 |
Sep 2023 | 0 | 10 |
Oct 2023 | 0 | 4440 |
Jan 2024 | 0 | 264 |
Mar 2024 | 0 | 3007 |
Apr 2024 | 0 | 249 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | ROMANO SARAH officer: Chief Fi.. | Common Stock | 75 | $4.23 | $317 | ||
Sale | SAPIRSTEIN JAMES director, officer: Chairman and.. | Common Stock | 174 | $4.23 | $736 | ||
Sale | SAPIRSTEIN JAMES director, officer: Chairman and.. | Common Stock | 1,887 | $4.96 | $9,360 | ||
Sale | ROMANO SARAH officer: Chief Fi.. | Common Stock | 1,120 | $4.96 | $5,555 | ||
Sale | ROMANO SARAH officer: Chief Fi.. | Common Stock | 98 | $4.2 | $412 | ||
Sale | SAPIRSTEIN JAMES director, officer: Chairman, Pr.. | Common Stock | 166 | $4.2 | $697 | ||
Sale | ROMANO SARAH officer: Chief Fi.. | Common Stock | 1,676 | $0.29 | $486 | ||
Sale | SAPIRSTEIN JAMES director, officer: President an.. | Common Stock | 2,764 | $0.29 | $802 | ||
Sale | CASAMENTO CHARLES J director | Common Stock | 10 | $0.43 | $4 | ||
Sale | CASAMENTO CHARLES J director | Common Stock | 6,053 | $0.3 | $1,816 |
-
What's the price of First Wave BioPharma stock today?
One share of First Wave BioPharma stock can currently be purchased for approximately $2.96.
-
When is First Wave BioPharma's next earnings date?
Unfortunately, First Wave BioPharma's (FWBI) next earnings date is currently unknown.
-
Does First Wave BioPharma pay dividends?
No, First Wave BioPharma does not pay dividends.
-
How much money does First Wave BioPharma make?
First Wave BioPharma has a market capitalization of 5.99M. First Wave BioPharma made a loss 15.79M US dollars in net income (profit) last year or -$9.47 on an earnings per share basis.
-
What is First Wave BioPharma's stock symbol?
First Wave BioPharma, Inc. is traded on the NASDAQ under the ticker symbol "FWBI".
-
What is First Wave BioPharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of First Wave BioPharma?
Shares of First Wave BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does First Wave BioPharma have?
As Jul 2024, First Wave BioPharma employs 9 workers, which is 10% less then previous quarter.
-
When First Wave BioPharma went public?
First Wave BioPharma, Inc. is publicly traded company for more then 8 years since IPO on 11 Oct 2016.
-
What is First Wave BioPharma's official website?
The official website for First Wave BioPharma is firstwavebio.com.
-
Where are First Wave BioPharma's headquarters?
First Wave BioPharma is headquartered at 777 Yamato Road, Boca Raton, FL.
-
How can i contact First Wave BioPharma?
First Wave BioPharma's mailing address is 777 Yamato Road, Boca Raton, FL and company can be reached via phone at +56 15897020.
First Wave BioPharma company profile:

First Wave BioPharma, Inc.
firstwavebio.comNASDAQ
9
Biotechnology
Healthcare
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Boca Raton, FL 33431
CIK: 0001604191
ISIN: US33749P4081
CUSIP: 33749P101